Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03179904
Title FASN Inhibitor TVB-2640 and Trastuzumab in Combination With Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic

Her2-receptor positive breast cancer


Paclitaxel + Trastuzumab + TVB-2640

Anastrozole + Trastuzumab + TVB-2640

Fulvestrant + Trastuzumab + TVB-2640

Exemestane + Trastuzumab + TVB-2640

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.